RPTP late January 2013 likely PDUFA date. AEGR proposed offering

Jun 14, 2012 No Comments by

Raptor Pharmaceutical Corp.  (Nasdaq:RPTP) today that the FDA accepted its New Drug Application (“NDA”) for Cysteamine Bitartrate Delayed-release Capsules (RP103), for the potential treatment of nephropathic cystinosis. A standard 10-month review was issued. A PDUFA date was not issued but the company released a press release on March 30, 2012 that it had filed its NDA, meaning a PDUFA date of approximately January 30, 2013. It also said that it expects the European Medicines Agency to issue a decision during 1H 2013.

Aegerion Pharmaceuticals, Inc (Nasdaq:AEGR) announced that it intends to offer for sale its common stock in an underwritten public offering.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “RPTP late January 2013 likely PDUFA date. AEGR proposed offering”

Leave a Reply